Drug intelligence / Profile preview

APMS-BSA-488

Development stage: Preclinical
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intraperitoneal

Overview

APMS-BSA-488 is a multifunctional micron-sized amorphous silica particle (APMS) modified with bovine serum albumin (BSA) and the Alexa Fluor 488 fluorophore. In the context of oncology research, specifically for malignant mesothelioma, it serves as a non-targeted control to evaluate the biodistribution and uptake of targeted APMS delivery systems. The APMS platform is designed for the localized delivery of chemotherapeutic drugs to tumor cell populations, aiming to reduce systemic toxicity and enhance therapeutic efficacy. APMS-BSA-488 allows researchers to distinguish between non-specific particle uptake and antibody-mediated targeting (such as anti-mesothelin modified particles).

Other names: non-targeted APMS control

Targets

Albumin-binding receptor

Beyond the preview

Go deeper on APMS-BSA-488.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APMS-BSA-488.

Explore the full profile